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Purpose or Objective: NRG/RTOG 0813 is a phase I/II study 
designed to determine the maximal tolerated dose (MTD) and 
efficacy of SBRT for NSCLC with centrally located tumors. We 
hereby report the primary endpoint of the phase I portion of 
the study. 
 
Material and Methods: Medically inoperable pts with biopsy 
proven, PET staged T1-2 (<5cm)N0M0 NSCLC and centrally 
located tumors (within or touching the zone of the proximal 
bronchial tree or adjacent to mediastinal or pericardial 
pleura) were successively accrued onto a dose-escalating 5 
fraction SBRT schedule ranging from 10-12 Gy/fraction 
delivered over 1.5-2 weeks. Dose-limiting toxicity (DLT) was 
defined as any grade 3 or worse toxicity (per CTCAE v.4) 
occurring within first year, possibly, probably, or definitely 
related to treatment from a pre-specified list of cardiac, 
esophageal, respiratory or neurological toxicities. Any 
potential DLT within the initial year post-SBRT could have led 
to dose reduction for subsequent patients accrued, using 
TITE-CRM (time-to-event continual reassessment method) 
statistical design. MTD was defined as SBRT dose associated 
with a 20% probability of DLT.  
 
Results: 120 pts were accrued Feb 2009 to Sept 2013 from 43 
participating centers. Numbers (n) accrued into each cohort, 
n eligible for analysis (20 pts were excluded as they did not 
receive protocol treatment (12) or were ineligible (8)), and n 
evaluable for DLT analyses (11 not evaluable, 10 of whom 
died in the first year without a DLT) are shown in the table. 
Pts were elderly (median age 72), slightly more females 
(57%), majority had performance status 0-1 (84%). Most 
cancers were T1 (65%) and squamous cell (45%). Median 
follow up was 26.6 months. There were 5 events that met the 
definition of DLTs; Table details the protocol pre-specified 
DLTs and the worst treatment-related AEs (ie occurring at 
any time). MTD is 12.0 Gy/fr; Bayesian-based probability of 
DLT on this arm was 7.2% (95% CI 2.8 -14.4%). The grade 5 
AEs occurred at a mean 13 mo postSBRT (range 5.5-14mo). 
 
 
 
Conclusion: The rates of toxicity pre-specified as DLT were 
relatively low. The highest dose level allowed by the protocol 
was reached, and associated with 7.2% rate of DLT. This 
phase I/II trial of SBRT provides data to inform patients of 
the potential toxicities with a 5 fraction SBRT schedule for 
centrally located NSCLC, but data on efficacy are still 
awaited. 
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Purpose or Objective: Patients with early stage non-small 
lung carcinoma (NSCLC) located centrally within the thorax 
present a therapeutic challenge with stereotactic body 
radiation therapy (SBRT). We compared outcomes of early 
stage NSCLC located in central and peripheral locations. 
 
Material and Methods: A total of 472 patients with early 
stage NSCLC were identified from a prospective IRB-approved 
thoracic SBRT registry. Tumors were classified as central if 
they were within 2 cm of the proximal bronchial tree or 
immediately adjacent to the mediastinal or pericardial 
pleura. Peripheral tumors were treated to 54 Gy in 3 
fractions, and central tumors to 50 or 55 Gy in 5 fractions. 
Patients were reviewed for overall survival (OS) calculated 
from completion of therapy and local failure (LF). The log-
rank test and Cox regression were used to identify factors 
predictive of OS and LF. 
 
Results: 127 patients had central tumors and 345 had 
peripheral tumors. Median follow-up was 30 months for living 
patients. For the entire cohort at 2 years, OS was 57% and LF 
was 10%. OS at 2 years was 50% for patients with central 
tumors and 60% for those with peripheral tumors (p=0.11). LF 
at 2 years was 19% for central lesions and 8% for peripheral 
lesions (p=0.08). On multivariate analysis, increasing tumor 
size (HR 1.21 per cm, 95% CI: 1.10-1.33, p<0.0001), 
increasing age-adjusted Charlson comorbidity score (HR 1.15 
per point, 95% CI: 1.09-1.20, p<0.0001), and worse KPS (HR 
10.1 per 10% loss, 95% CI: 10.1-10.2, p=0.0003), but not 
location predicted for worse OS. Only increasing tumor size 
(HR 1.37/cm, 95% CI: 1.06-1.78, p=0.02) predicted for LF on 
multivariate analysis. 
 
Conclusion: The use of five SBRT fractions of 10-11 Gy for 
central early stage NSCLC results in similar outcomes as 
peripheral early stage NSCLC treated in three SBRT fractions 
of 18 Gy. Larger tumors result in worse outcomes suggesting 
the need for additional treatment strategies. 
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Purpose or Objective: Pulmonary tumours are subject to 
respiratory motion which induces PET/MRI artefacts and 
imposes to use specific additional margins when treated by 
radiotherapy (RT). Gating techniques can solve these issues 
by stabilizing lung targets, and sustaining breath-holds in 
maximal inspiration (MI). However, these are limited by the 
patient’s capacity to hold his breath. The purpose of this 
work was to implement a new non-invasive respiratory 
assistance using high frequency percussive ventilation (HFPV -
Percussionaire®; Idaho, USA), and to report its first clinical 
use in maintaining breath holds long enough during chest 
imaging and complex RT treatments. 
 
Material and Methods: ethical committee approval was 
obtained to conduct a clinical study, after evaluating its 
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feasibility and tolerability in a cohort of volunteers. HFPV 
was applied in patients eligible for breast 3DRT, lung 
stereotactic RT, locally-advanced lung RT. Durations of 
breath hold obtained under HFPV for each clinical situation 
were reported. Dosimetric parameters in free breathing (FB), 
MI gating, or HFPV conditions were compared. The HFPV was 
also adapted and tested for thoracic MRI and PET. 
 
Results: For volunteers, HFPV offered a mean duration time 
for apnea like breath hold of 10.6 minutes. Transferred in 
patients, this percussion assisted radiotherapy (PART) was 
applied with good tolerance in the first 3 patients without 
treatment breaks during the overall fractionated RT. All 
together, 50 RT fractions have been delivered under PART, 
and the mean duration of apnea-like breath hold necessary 
for “beam on” was 7.61 minutes (SD 2.3). HFPV offered a 
favorable dosimetric profile when compared to MI or FB for 
these 3 clinical RT situations (table). In addition, the HFPV 
markedly improved both PET and MRI image quality in 
detecting small pulmonary lesions (figure).  
 
Conclusion: the HPFV allowed prolonged apnea-like breath 
hold that could be used both for fractionated RT and chest 
imaging. These preliminary results were very promising and 
prompt to develop larger studies to evaluate its 
reproducibility and potential clinical benefits both for 
radiotherapy and for lung PET/MRI imaging. 
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Purpose or Objective: Moving away from guideline-based 
treatment to a more personalized approach requires accurate 
outcome prediction. Yet, physicians’ predictions of survival 
and toxicity after lung radiotherapy are as good as flipping a 
coin (Oberije et al.,Radiother. Oncol. 2014). We hypothesize 
that the physicians’ knowledge of complex interactions 
between clinical variables and treatment outcomes is a 
valuable resource for prediction modelling. Therefore, we 
created and compared expert-based and data-driven 
prediction models. The predicted endpoints are severe 
dyspnea (CTCAE dyspnea scores ≥ 2) and increases in the 
CTCAE dyspnea score after radiotherapy (RT). Severe dyspnea 
occurs in approximately 15% of all patients treated with lung 
radiotherapy and has a possibly severe impact on patients’ 
quality of life. 
 
Material and Methods: Data from 1152 lung cancer patients 
treated in clinical routine (2006-2015, partially incomplete 
data) were used. Seven experts selected causal links between 
19 variables (patient, disease, treatment, and dose-related 
variables) and post-RT dyspnea to construct Bayesian 
Networks (BNs). Their individual choices, the consensus 
choices, and a data-driven algorithm were used to build BNs 
for both endpoints. 80% of the data were used for model 
building. Validation was performed for all models in terms of 
discrimination (Area under the Curve) in the remaining 20% of 
the data, isolated before modelling. 
 
Results: Expert-based networks were more complex than 
algorithmically-constructed networks (range: 7-30 vs. 3-6 
arcs) but their predictions for severe dyspnea in non-dyspneic 
patients were not significantly better (see 95% confidence 
intervals in table). Furthermore, all models besides expert 
model 6 were not different from chance as AUC confidence 
intervals include 0.5. Models predicting increases in CTCAE 
dyspnea scores performed better (all models’ AUCs > 0.6) and 
different from 0.5 with 97.5% confidence. Among those, the 
data-driven approach performed significantly better than 3 of 
the 7 expert models. Consensus networks between experts 
did not improve the predictive performance. 
 
 
 
 
 
Conclusion: The results suggest that reliable predictions of 
post-RT dyspnea scores ≥ 2 in non-dyspneic patients are not 
achievable with any of the presented models. Clinical routine 
appears to still miss appropriate biomarkers. In contrast, 
prediction modelling for post-RT increases in dyspnea is 
feasible with expert knowledge as well as data-driven 
algorithms. The comparison between expert- and data-driven 
modelling indicates that data-driven modelling can yield 
simpler models with similar performance as expert-driven 
modelling. 
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Purpose or Objective: The role of thoracic radiotherapy 
(TRT) in extensive stage small-cell lung cancer (ES-SCLC) has 
been evaluated in a recent phase 3 randomised control trial. 
The results of the Chest Radiotherapy Extensive stage Small 
cell lung cancer Trial (CREST) were published in the Lancet 
(2015,385,36-42). This study showed that TRT did not 
significantly improve 1-year overall survival, which was the 
primary endpoint. However there was a significant 
